Ocular side effects following intravitreal injection therapy for retinoblastoma

A systematic review

Stephen J. Smith, Brian D. Smith, Brian G. Mohney

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: To describe the ocular side effects in patients receiving intravitreal injection therapy (IViT) for retinoblastoma. Methods: PubMed (1946-present), Scopus (all years), Science Citation Index (1900-present) and Conference Proceedings Citation Index - Science (1990-present) electronic databases were searched to identify all published reports of therapeutic intravitreal injections for retinoblastoma in humans. Results: Ten studies with original IViT ocular side effect data were included in this systematic review. In these combined reports, a total of 1287 intravitreal injections were given to 306 eyes of 295 patients, with a mean follow-up of 74.1 months. Two hundred sixty-one (88.5%) patients received comparatively standard melphalan IViT doses (8-30 mcg). Ocular side effects occurred in 38 patients (17 significant, 21 minor). The proportion of patients experiencing potentially significant ocular side effects following standard melphalan IViT regimens was 0.031 (8/261; 95% CI 0.013 to 0.06). The side effects of these eight included iris atrophy in three, two each with chorioretinal atrophy and vitreous haemorrhage and one with retinal detachment. Of the other nine patients with significant complications, five experienced sight-threatening complications following dramatic dose escalations (four with melphalan, one with thiotepa), three experienced complications that are commonly associated with concurrent therapies given to these patients and one had a retinal detachment. Of the 61 patients receiving IViT via safety-enhancing injection techniques, all six significant side effects were either attributed to the therapeutic dose or confounded by concurrent treatments. Conclusions: Significant ocular complications following IViT for retinoblastoma are uncommon, and this risk may be reduced further by the use of careful injection technique and standard dosing regimens. Care must be taken in the dosing of intravitreal treatments to avoid potentially irreversible vision loss.

Original languageEnglish (US)
Pages (from-to)292-297
Number of pages6
JournalBritish Journal of Ophthalmology
Volume98
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Intravitreal Injections
Retinoblastoma
Melphalan
Therapeutics
Retinal Detachment
Atrophy
Thiotepa
Vitreous Hemorrhage
Injections
Iris
PubMed
Databases

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Ocular side effects following intravitreal injection therapy for retinoblastoma : A systematic review. / Smith, Stephen J.; Smith, Brian D.; Mohney, Brian G.

In: British Journal of Ophthalmology, Vol. 98, No. 3, 03.2014, p. 292-297.

Research output: Contribution to journalArticle

Smith, Stephen J. ; Smith, Brian D. ; Mohney, Brian G. / Ocular side effects following intravitreal injection therapy for retinoblastoma : A systematic review. In: British Journal of Ophthalmology. 2014 ; Vol. 98, No. 3. pp. 292-297.
@article{c617b81992514e6cbe1378a32549fb45,
title = "Ocular side effects following intravitreal injection therapy for retinoblastoma: A systematic review",
abstract = "Purpose: To describe the ocular side effects in patients receiving intravitreal injection therapy (IViT) for retinoblastoma. Methods: PubMed (1946-present), Scopus (all years), Science Citation Index (1900-present) and Conference Proceedings Citation Index - Science (1990-present) electronic databases were searched to identify all published reports of therapeutic intravitreal injections for retinoblastoma in humans. Results: Ten studies with original IViT ocular side effect data were included in this systematic review. In these combined reports, a total of 1287 intravitreal injections were given to 306 eyes of 295 patients, with a mean follow-up of 74.1 months. Two hundred sixty-one (88.5{\%}) patients received comparatively standard melphalan IViT doses (8-30 mcg). Ocular side effects occurred in 38 patients (17 significant, 21 minor). The proportion of patients experiencing potentially significant ocular side effects following standard melphalan IViT regimens was 0.031 (8/261; 95{\%} CI 0.013 to 0.06). The side effects of these eight included iris atrophy in three, two each with chorioretinal atrophy and vitreous haemorrhage and one with retinal detachment. Of the other nine patients with significant complications, five experienced sight-threatening complications following dramatic dose escalations (four with melphalan, one with thiotepa), three experienced complications that are commonly associated with concurrent therapies given to these patients and one had a retinal detachment. Of the 61 patients receiving IViT via safety-enhancing injection techniques, all six significant side effects were either attributed to the therapeutic dose or confounded by concurrent treatments. Conclusions: Significant ocular complications following IViT for retinoblastoma are uncommon, and this risk may be reduced further by the use of careful injection technique and standard dosing regimens. Care must be taken in the dosing of intravitreal treatments to avoid potentially irreversible vision loss.",
author = "Smith, {Stephen J.} and Smith, {Brian D.} and Mohney, {Brian G.}",
year = "2014",
month = "3",
doi = "10.1136/bjophthalmol-2013-303885",
language = "English (US)",
volume = "98",
pages = "292--297",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Ocular side effects following intravitreal injection therapy for retinoblastoma

T2 - A systematic review

AU - Smith, Stephen J.

AU - Smith, Brian D.

AU - Mohney, Brian G.

PY - 2014/3

Y1 - 2014/3

N2 - Purpose: To describe the ocular side effects in patients receiving intravitreal injection therapy (IViT) for retinoblastoma. Methods: PubMed (1946-present), Scopus (all years), Science Citation Index (1900-present) and Conference Proceedings Citation Index - Science (1990-present) electronic databases were searched to identify all published reports of therapeutic intravitreal injections for retinoblastoma in humans. Results: Ten studies with original IViT ocular side effect data were included in this systematic review. In these combined reports, a total of 1287 intravitreal injections were given to 306 eyes of 295 patients, with a mean follow-up of 74.1 months. Two hundred sixty-one (88.5%) patients received comparatively standard melphalan IViT doses (8-30 mcg). Ocular side effects occurred in 38 patients (17 significant, 21 minor). The proportion of patients experiencing potentially significant ocular side effects following standard melphalan IViT regimens was 0.031 (8/261; 95% CI 0.013 to 0.06). The side effects of these eight included iris atrophy in three, two each with chorioretinal atrophy and vitreous haemorrhage and one with retinal detachment. Of the other nine patients with significant complications, five experienced sight-threatening complications following dramatic dose escalations (four with melphalan, one with thiotepa), three experienced complications that are commonly associated with concurrent therapies given to these patients and one had a retinal detachment. Of the 61 patients receiving IViT via safety-enhancing injection techniques, all six significant side effects were either attributed to the therapeutic dose or confounded by concurrent treatments. Conclusions: Significant ocular complications following IViT for retinoblastoma are uncommon, and this risk may be reduced further by the use of careful injection technique and standard dosing regimens. Care must be taken in the dosing of intravitreal treatments to avoid potentially irreversible vision loss.

AB - Purpose: To describe the ocular side effects in patients receiving intravitreal injection therapy (IViT) for retinoblastoma. Methods: PubMed (1946-present), Scopus (all years), Science Citation Index (1900-present) and Conference Proceedings Citation Index - Science (1990-present) electronic databases were searched to identify all published reports of therapeutic intravitreal injections for retinoblastoma in humans. Results: Ten studies with original IViT ocular side effect data were included in this systematic review. In these combined reports, a total of 1287 intravitreal injections were given to 306 eyes of 295 patients, with a mean follow-up of 74.1 months. Two hundred sixty-one (88.5%) patients received comparatively standard melphalan IViT doses (8-30 mcg). Ocular side effects occurred in 38 patients (17 significant, 21 minor). The proportion of patients experiencing potentially significant ocular side effects following standard melphalan IViT regimens was 0.031 (8/261; 95% CI 0.013 to 0.06). The side effects of these eight included iris atrophy in three, two each with chorioretinal atrophy and vitreous haemorrhage and one with retinal detachment. Of the other nine patients with significant complications, five experienced sight-threatening complications following dramatic dose escalations (four with melphalan, one with thiotepa), three experienced complications that are commonly associated with concurrent therapies given to these patients and one had a retinal detachment. Of the 61 patients receiving IViT via safety-enhancing injection techniques, all six significant side effects were either attributed to the therapeutic dose or confounded by concurrent treatments. Conclusions: Significant ocular complications following IViT for retinoblastoma are uncommon, and this risk may be reduced further by the use of careful injection technique and standard dosing regimens. Care must be taken in the dosing of intravitreal treatments to avoid potentially irreversible vision loss.

UR - http://www.scopus.com/inward/record.url?scp=84894063122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894063122&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2013-303885

DO - 10.1136/bjophthalmol-2013-303885

M3 - Article

VL - 98

SP - 292

EP - 297

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 3

ER -